Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22)

被引:13
作者
Sun, XP [1 ]
Medeiros, LJ [1 ]
Lu, D [1 ]
Rassidakis, GZ [1 ]
Bueso-Ramos, C [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
关键词
bone marrow; acute myeloid leukemia; inv(16); eosinophilia; dysplasia; proliferation; apoptosis;
D O I
10.1309/PGNT8LGN9AR4QVAJ
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Acute myeloid leukemia (AML) with inv(16)(p13q22), also known as M4Eo, is a distinct type of AML with a favorable prognosis associated with abnormal bone marrow eosinophils. We reviewed the morphologic findings of archival bone marrow specimens with M4Eo, specifically assessing for dysplasia, and performed immunohistochemical studies to assess the growth fraction using the MIB-1 (Ki-67) antibody. We also assessed the apoptotic rate by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick end labeling. All assessable cases had more than 10% dysplastic forms in at least 1 lineage. Seventeen cases had 10% or more dysplastic forms, and 3 cases had more than 50% dysplastic forms in at least 2 lineages. Immunoreactivity for Ki-67 was higher in M4Eo than in other AML types (P = .000). The apoptotic rate in M4Eo was similar to other AML types (P =. 724). Our data show that dysplasia is a prominent feature, but not a prognostic indicator, in M4Eo. M4Eo is associated with a significantly higher proliferation rate than other AML types.
引用
收藏
页码:236 / 245
页数:10
相关论文
共 35 条
[1]  
ARTHUR DC, 1983, BLOOD, V61, P994
[2]  
BERNARD P, 1989, LEUKEMIA, V3, P740
[3]   Acute myeloid leukemia with inv(16)(p13q22):: Involvement of cervical lymph nodes and tonsils is common and may be a negative prognostic sign [J].
Billström, R ;
Ahlgren, T ;
Békássy, AN ;
Malm, C ;
Olofsson, T ;
Höglund, M ;
Mitelman, F ;
Johansson, B .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (01) :15-19
[4]   A MORPHOLOGIC AND CYTOCHEMICAL STUDY OF ACUTE MYELOMONOCYTIC LEUKEMIA WITH ABNORMAL MARROW EOSINOPHILS ASSOCIATED WITH INV(16)(P13Q22) [J].
BITTER, MA ;
LEBEAU, MM ;
LARSON, RA ;
ROSNER, MC ;
GOLOMB, HM ;
ROWLEY, JD ;
VARDIMAN, JW .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1984, 81 (06) :733-741
[5]  
Bloomfield CD, 1998, CANCER RES, V58, P4173
[6]   CBFβ-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents [J].
Britos-Bray, M ;
Ramirez, M ;
Cao, WS ;
Wang, XP ;
Liu, PP ;
Civin, CI ;
Friedman, AD .
BLOOD, 1998, 92 (11) :4344-4352
[7]  
BRUNNING RD, 2001, PATHOLOGY GENETICS T, P70
[8]  
BRUNNING RD, 2001, PATHOLOGY GENETICS T, P82
[9]  
BRUNNING RD, 2001, PATHOLOGY GENETICS T, P88
[10]   CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells [J].
Cao, WS ;
BritosBray, M ;
Claxton, DF ;
Kelley, CA ;
Speck, NA ;
Liu, PP ;
Friedman, AD .
ONCOGENE, 1997, 15 (11) :1315-1327